Regulatory role of KCa3.1 in immune cell function and its emerging association with rheumatoid arthritis

Yi Lin1,2†, Ying-Jie Zhao1†, Hai-Lin Zhang1,2, Wen-Juan Hao1,2, Ren-Di Zhu1,2, Yan Wang1,2, Wei Hu1,3* and Ren-Peng Zhou1,3*

1Department of Clinical Pharmacology, The Second Hospital of Anhui Medical University, Hefei, China, 2Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China, 3The Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Anhui Medical University, Hefei, China

Rheumatoid arthritis (RA) is a common autoimmune disease characterized by chronic inflammation. Immune dysfunction is an essential mechanism in the pathogenesis of RA and directly linked to synovial inflammation and cartilage/bone destruction. Intermediate conductance Ca²⁺-activated K⁺ channel (KCa3.1) is considered a significant regulator of proliferation, differentiation, and migration of immune cells by mediating Ca²⁺ signal transduction. Earlier studies have demonstrated abnormal activation of KCa3.1 in the peripheral blood and articular synovium of RA patients. Moreover, knockout of KCa3.1 reduced the severity of synovial inflammation and cartilage damage to a significant extent in a mouse collagen antibody-induced arthritis (CAIA) model. Accumulating evidence implicates KCa3.1 as a potential therapeutic target for RA. Here, we provide an overview of the KCa3.1 channel and its pharmacological properties, discuss the significance of KCa3.1 in immune cells and feasibility as a drug target for modulating the immune balance, and highlight its emerging role in pathological progression of RA.

KEYWORDS
KCa3.1, immune cells, joint inflammation, rheumatoid arthritis, synovitis

Introduction

Rheumatoid arthritis (RA) is an autoimmune disease that primarily affects the joints. The average global incidence is 0.5% to 1.0%, with genetic factors accounting for approximately 60% risk of RA (1). The primary goal of RA therapy is to restore the immune balance and reduce synovial inflammation and joint damage. The traditional drug of RA ranges from disease-modifying anti-rheumatic drugs (DMARDs) (eg, methotrexate and Janus kinase inhibitor tofacitinib) to biologic agents (eg, tumor
Overview of KCa3.1

KCa3.1 is a multifunctional intermediate conduction channel also known as IKCa1, SK4, IK-1 or KCa4 (10, 11). This channel belongs to a gene family consisting of all Ca\(^{2+}\)-activated K\(^+\) channels. The International Union of Pharmacology has now classified the gene family into three groups: KCa1.1 (BK, big-conductance K\(^+\) channel), KCa2.1, KCa2.2, KCa2.3 (SK, small-conductance K\(^+\) channel) and KCa3.1 (IK, intermediate-conductance K\(^+\) channel) (12). KCa3.1 is a membrane-spanning protein composed of four \(\alpha\)-subunits (13). Each \(\alpha\)-subunit has six transmembrane segments (S1-S6) with a pore motif between S5 and S6. The pore region is formed by the transmembrane helices S5 and S6 in the symmetrical center of the tetramer, generating a K\(^+\) conduction pathway (14). In genetics, the coding gene KCNN4 is located at the q13.2 locus of human chromosome 19 (15, 16). The encoded protein contains 427 amino acids with a short N-terminal domain and long C-terminal tail. The C-lobe of CaM constitutively binds to CAM-binding domain (CAMBD) 1 (positions 312-329) in a Ca\(^{2+}\)-independent manner at the C-terminus of KCa3.1, whereas the CaM N-lobe barely binds to the channel and its binding pocket remains closed. In the presence of high Ca\(^{2+}\), the N-lobe of CaM binds with Ca\(^{2+}\) and rearranges into an open conformation. The N-lobe of CaM pulls the S4A (first helix of the S4-S5 linker) helix down, keeping the S5B (tightly coupled to the pore-lining S6 helix) away from the pore axis. This expands the S6 helical bundle and eventually opens the pore (17). The N-lobe of CaM binds to KCa3.1 at CAMBD2A (a nearby segment, positions 344-353) in the same subunit and CAMBD2B (a distal segment, positions 360-373) in an adjacent subunit (18). Furthermore, a pivotal role of channel tetramerization and trafficking of two leucine zipper (LZ) motifs in the N- and C-termini has been reported (19, 20). The structure of KCa3.1 is shown schematically in Figure 1.

Here we focus on the transcriptional regulation, splicesome regulation and epigenetic regulation of KCa3.1 (21). At the transcriptional level, activation protein-1 (AP-1) in conjunction with transcription factor Ikaros-2, was demonstrated to enhance KCa3.1 channel expression, which promoted the mitogenesis of preactivated lymphocytes (22). Additionally, laminar shear stress upregulates endothelial KCa3.1 by binding of AP-1 and cAMP response element (CRE) to promoter in a CaMK/Akt/p300 pathway-dependent manner (23). Mutation of the AP-1 binding motif in T cells as well as the transfection of AP-1 decoy oligonucleotides into cardiac fibroblasts were shown to significantly downregulate the expression of KCa3.1 (22, 24). Furthermore, two NF-kB binding sites were identified in the promoter region of KCa3.1, and the up-regulation of KCa3.1 in colon cancer cells was mediated in an NF-kB-dependent manner (25). A functional repressor element 1-silencing transcription factor (REST or NRSF) was confirmed to be a negative regulator of KCa3.1 transcription (26). In a study on tumors, histone deacetylase 2 (HDAC2) and HDAC3 were found to downregulate KCa3.1 transcript levels in a REST-independent and insulin-like growth factor-binding protein 5 (IGFBP5)-independent manner in the breast cancer cell line, TMB-1 (27). Meanwhile, HDAC2 and HDAC3 were found to be involved in the epigenetic regulation of KCa3.1 in the KCa3.1-expressing human prostate cancer cell line, PC-3. Epigenetically, KCNN4 is hypermethylated in memory B cells in common variable immunodeficiency (CVID) individuals relative to healthy individuals (28). However, in a genome-wide DNA methylation analysis, Bulk et al. found that the KCNN4 promoter was...
hypomethylated in lung cancer (29). Besides, Ohya et al. identified novel spliced variants of KCa3.1 (human(h) KCa3.1b) from the human thymus, which differs from hKCa3.1a for the lack of the N-terminal domains. The study suggests that the N-terminal domain of KCa3.1 is essential for channel trafficking to the plasma membrane (30). Moreover, Du et al. showed that KCNN4 was regulated by several microRNAs, such as miR-204-5p studied in the research of pancreatic ductal adenocarcinoma (PDAC) (31).

KCa3.1 is located in the lung, distal colon, and immune-related tissues, such as thymus, bone marrow, and lymph nodes (32). In-depth studies have shown that KCa3.1 is almost expressed in non-excitable cells, such as fibroblasts, lymphocytes, and other immune cells. At the cellular level, electrophysiological and pharmacological characterization studies have identified the presence of KCa3.1 in plasmalemma and mitochondrial membrane (33). KCa3.1 channels are additionally voltage-independent and unaffected by membrane potential, with Ca2+-dependent and inwardly rectifying properties of intermediate conduction (34). Functionally, basolateral KCa3.1 provides the driving force for Cl- secretion induced by activators such as Ca2+ in human and rat colon (35). KCa3.1 is also involved in regulation of cell volume in lymphocytes (36). Similarly, patch-clamp studies showed that the CFT1-LCFSN cell, a cystic fibrosis airway cell line, copes with hypotonic challenge via increasing the

---

**FIGURE 1**

Schematic representation of the structure of KCa3.1. A functional Ca2+-activated intermediate conductance K+ channel (KCa3.1) comprises four α subunits organized around a central pore through which K+ flows out of the cell. (A) KCa3.1 channel composed of four α subunits. (B) Top view of four α subunits around the central pore. (C) Schematic representation of a single KCa3.1 subunit, showing a total of 427 amino acids and consists of six transmembrane segments, named S1-S6. The K+ ion conduction pore is located between the loop and S6, containing the GYGD K+ channel pore sequence. CaM N-lobe binds to CAMBD2A and CAMBD2B with Ca2+, leading to channel opening. (Created with BioRender.com).
KCa3.1 current (37). Moreover, the KCa3.1 channel is activated at elevated cytosolic Ca\(^{2+}\) concentrations of above 100 nM. Substantial activation of the KCa3.1 channel leads to K\(^+\) efflux, thereby restoring and stabilizing the fully hyperpolarized membrane potential to maintain a continuous driving force of Ca\(^{2+}\) influx (38). While Ca\(^{2+}\) is indispensable for various physiological activities of the body, continuous influx is necessary for activation, proliferation and other physiological function of immune cells and cytokine production (39). Thus, the functions of KCa3.1 described above suggest the potential of targeting KCa3.1 in the treatment of diseases associated with immune imbalance.

**Activators and inhibitors of KCa3.1**

The pharmacological effects of the KCa3.1 channel have been widely explored and its activators and inhibitors analyzed in various diseases (Table 1). The majority examples of channel activators are documented in the literature related to cardiovascular diseases, neurological diseases and immune diseases. For instance, 1-ethyl-2-benzimidazolidinone (1-EBIO) serves as a direct and potent specific activator of KCa3.1 via increasing sensitivity of the channel to resting levels of Ca\(^{2+}\) (43). A dichloro analog of benzimidazolidinone, 5,6-dichloro-1-EBIO (DC-EBIO), is reported to be 30 times more potent than EBIO (44). Naphtho [1, 2-d] thiazole-2-ylamine (SKA-31) and its optimized product, 5-methylnaphtho [2,1-d] oxazole-2-amine (SKA-121), act in a similar manner to EBIO (45). Another preliminary study showed for the first time that 6,7-dichloro-1H-indole-2,3-dione-3-oxime (NS309) positively regulates KCa3.1 with higher potency and selectivity than 1-EBIO in the HEK-293 cells (human embryonic kidney cells). The above findings indicate that NS309 presents an excellent alternative to 1-EBIO as a pharmacological tool in KCa3.1 activation-related research (46). In addition, chlorozaconozole (CZ) and zoazolamide (ZOX) are often used clinically as pharmacological activators of the KCa3.1 channel and have entered Phase IV and Phase II clinical trials, respectively (51). Classical methylxanthine compounds, including theophylline, 3-isobutyl-1-methylxanthine (IBMX) and caffeine, are reported to interact directly with channel proteins to activate KCa3.1 (47). Gerlach et al. demonstrated that ATP activates KCa3.1 in excised, inside-out patches in a protein kinase A inhibitor 5-24-dependent manner (52). In their experiments, ATP specifically activated chimera containing the KCa3.1 C-terminal amino acids His\(^{209}\)-Lys\(^{427}\), but not other highly homologous Ca\(^{2+}\)-activated K\(^+\) channels. In terms of indirect activation, the human single cell-dependent protein kinase (PKA) site (S334A) on the KCa3.1 \(\alpha\) subunit is dependent on phosphorylation of PKA to reduce binding of CaM to the KCa3.1 channel. PKA signaling pathway inhibitors, such as PKI14-22, Rp-8-Br-cAMPS, and N-[2-(4-bromocinnamylamino) ethyl]-5-isouquinoline (H-89), significantly reversed downregulation of KCa3.1 channel, thereby restoring its function, while Sp-8-Br-cAMPS, a PKA activator, exerted the opposite effect (48, 53). Interestingly, PKA-mediated phosphorylation was shown to have no regulatory effect on KCa3.1 channel in the above study (50). Moreover, a monoclonal blocking antibody against programedmed death 1, pembrolizumab, has been identified that promotes KCa3.1 activity and concomitantly increases Ca\(^{2+}\) flux in cytotoxic T cells of patients immediately after treatment (54, 55). In conclusion, most KCa3.1 channel activators have low potency and poor selectivity and modulate other ion channels simultaneously.

KCa3.1 channel inhibitors are divided into two main categories: peptides and small molecule inhibitors. Peptide blockers bind to the outer vestibule of the channel and form multi-point contacts with channel residues whereas small-molecule blockers pass through the membrane and bind the cavity from the inside, blocking K\(^+\) outflow (38). The majority of KCa3.1 channel peptide inhibitors are toxins polypeptides. The most common is the scorpion toxin Glu32-charybdotoxin, initially isolated from *Leiurus quinquestriatus*. Nevertheless, the scorpion toxin peptide has low selectivity for KCa3.1 and additionally shows activity against both KCa1.1 and Kv1.3 channel (a voltage-gated K\(^+\) channel) (56, 57). Maurotoxin (MTX) (58) and urototoxin (\(\alpha\)-KTx6) (59) display affinity for KCa3.1 but also affect the Kv1.2 channel (a voltage-gated K\(^+\) channel). Accordingly, toxin polypeptide KCa3.1 channel blockers have limited experimental value for in vivo research on KCa3.1 due to their low specificity and are more commonly used to investigate the pharmacological properties of KCa3.1 in vitro (60).

Small-molecule inhibitors of KCa3.1, primarily derived from the antibacterial drug clortimazole, effectively block the channel and inhibit mitosis of activated prolymphocytes (22). However, clortimazole inhibits cytochrome P450 enzymes in vivo, causing severe side-effects, which limits its pharmaceutical value (45). A derivative inhibitor of clortimazole, 1-[(2-chlorophenyl) diphenylmethyl]-1H-pyrazole (TRAM-34), was further developed, which could avoid the adverse reactions of cytochrome P450 enzyme inhibition (61). TRAM-34 is the most commonly used KCa3.1 channel inhibitor in pharmacological experiments. Mechanistically, TRAM-34 binds threonine 250 and valine 275 in the pore cavity of the KCa3.1 channel, preventing penetration of ion (62).4-[(3- (trifluoromethyl) phenyl) methyl]-2H-1, 4-benzothiazin-3 (4H)-one (NS6180) inhibits KCa3.1 channel activity using the same mechanism as TRAM-34 but has low bioavailability and is therefore only suitable for topical therapy. Senicapoc, also known as ICA-17043, is a potent and selective blocker of KCa3.1. Compared to other receptors, senicapoc displays higher selectivity for KCa3.1 and lower possibility of off-target effects (63, 64). A number of novel compounds have been synthesized using the L-type Ca\(^{2+}\) channel blocker nifedipine as the template, such as cyclohexadiene 4 (32) and the nano-affinity KCa3.1 channel inhibitor cyclohexadiene lactone composed of cyclohexadiene (4), and phenyl-4H-pyran. Due to the difficulty in synthesizing phenyl-4H-pyran and its short
### TABLE 1  Inhibitors and Activators of KCa3.1.

| Activators/ Inhibitors | Substances | Structure/formula | IC$_{50}$/EC$_{50}$ | Experimental cells | Description | Clinical trial | References |
|------------------------|------------|-------------------|---------------------|---------------------|-------------|----------------|------------|
| Channel activators     | 1-EBIO     | ![Structure](image1) | 84 μM(EC$_{50}$)    | Xenopus oocytes      | Increase channel open rate | \            | (29, 32)   |
|                        | DC-EBIO    | ![Structure](image2) | Test at 100 μM      | Capan-1 cells       | Increase channel open rate | \            | (40, 41)   |
|                        | SKA-31     | ![Structure](image3) | 260 nM (EC$_{50}$)  | COS-7 cells         | open channel | \            | (30)       |
|                        | SKA-121    | ![Structure](image4) | 110 nM (EC$_{50}$)  | COS-7 cells         | open channel | \            | (30)       |
|                        | NS309      | ![Structure](image5) | 10 nM (EC$_{50}$)   | HEK-293 cell        | open channel | \            | (31)       |
|                        | CZ         | ![Structure](image6) | 98 μM(EC$_{50}$)    | Xenopus oocytes      | Increase channel open rate | Phase I-IV    | (32)       |
|                        | ZOX        | ![Structure](image7) | Test at 300 μM      | Xenopus oocytes      | Increase channel open rate | Phase I-II    | (32)       |
|                        | theophylline | ![Structure](image8) | Test at 0~1500 μM   | HEK-293 cell         | Mandatory Ca$^{2+}$-dependent, independent of phosphorylation | Phase I-IV;   | (33)       |
| Channel activators     | IBMX       | ![Structure](image9) | Only test at 1mM    | HEK-293 cell         | Mandatory calcium dependence | \            | (33)       |
|                        | Caffeine   | ![Structure](image10) | Only test at 1mM    | HEK-293 cell         | Mandatory calcium dependence | Phase I-IV    | (33)       |
|                        | ATP        | ![Structure](image11) | Only test at 100 μM | Human microglia      | activate purinergic receptors, free [Ca$^{2+}$] | Phase I-IV    | (42)       |
|                        | PKI14-22   | C$_{33}$H$_{66}$N$_{10}$O$_{12}$ | Only test at 10M   | MLS-9 microglia, primary rat microglia | Inhibit PKA, increase current | \            | (35)       |
|                        | Rp-8-Br-cAMPS | ![Structure](image12) | Test at 10M, 100μM | MLS-9 microglia, HEK-293 cell, post-SE neurons | Inhibit PKA, increase current | \            | (35, 36)  |
|                        | H-89       | ![Structure](image13) | Test at 1μM, 10 μM  | HEK-293 cell         | Inhibit PKA | \            | (36)       |

(Continued)
half-life after intravenous injection (62), the compound is not a suitable replacement for TRAM-34 as a KCa3.1 inhibitor. Clinically, the antihypertensive drug nitrendipine blocks KCa3.1 channel at a dose of 100 nM (65). Previous studies have shown that in the PI3K-PI(3)P signaling pathway, LY29400259 (a phosphatidylinositol 3-kinase inhibitor) (55) and ellagic acid (a nucleoside diphosphate kinase B kinase inhibitor) (66), prevent phosphorylation of specific group amino acid and inhibit activity of the KCa3.1 channel. Recently, Licochalconer A, a chalcone compound extracted from licorice, was shown to block KCa3.1 in a concentration-dependent manner, with anti-inflammatory effects (67). In general, the pharmacological effects of the KCa3.1 channel are relatively well characterized and meet the pharmacological needs in the relevant studies. However, the most rigorous obstacle to clinical application of KCa3.1 modulators is almost associated with their low selectivity, so it is of great significance to explore highly specific drugs targeting KCa3.1 for conforming to clinical use.

Abnormal expression of KCa3.1 in rheumatoid arthritis

RA is an autoimmune disease characterized by inflammation of the synovium, with the essential site of inflammation identified as the synovial lining. In the process of lymphocyte activation and pathological function in rheumatoid arthritis, the increase of transient intracellular free calcium level plays a crucial role. A study have found that compared with healthy
people, RA patients have elevated basal cytoplasmic free calcium level ([Ca\(^{2+}\)\(_{cyt}\)]) and abnormal activation of KCa3.1 channel to maintain calcium influx in peripheral T lymphocytes (68). Additionally, Ca\(^{2+}\)-activated K\(^{+}\) currents with the characteristics of KCa3.1 channel were detected in synovial fibroblasts from RA patients. TGF-β1-induced KCa3.1 overexpression stimulates the proliferation and mediator secretion of synovial fibroblasts, which can be suppressed by KCa3.1 inhibitors. This result supports the theory that KCa3.1 is closely related to synovial inflammation (8). In addition, KCNN4 is required for fusion of macrophages to form osteoclasts or multinucleated macrophages (MGCs) during the immune response to RA (69). KCa3.1 is expressed in both physiological and inflammatory osteoclast formation and is the only channel in the Ca\(^{2+}\)-activated K\(^{+}\) channel family that is upregulated during the process of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation. The collective results confirm an association of abnormal expression of KCa3.1 with pathogenesis of RA.

Experimental studies on animal models suggest that KCa3.1 is significantly associated with inflammation and pathogenesis of RA. In a collagen antibody-induced arthritis (CAIA) model, alleviated joint inflammation and tissue damage was observed in KCNN4\(^{-/-}\) mice compared to KCNN4\(^{+/+}\) mice (69). One extremely interesting phenomenon was that collagen-induced arthritis (CIA) KCNN4\(^{-/-}\) mice did not develop autoimmune arthritis (70). Specifically, following intradermal injection of chicken collagen type II into the base of the tail of KCNN4\(^{-/-}\) mice on days 0 and 21, no KCNN4\(^{-/-}\) mice developed clinical evidence or histological signs of arthritis, in contrast to wild-type mice. Notably, the CIA KCNN4\(^{-/-}\) model indicates a possible pro-inflammatory effect of KCa3.1 in RA. However, the specific mechanisms by which deficiency of KCNN4 induces resistance against joint inflammation in CIA models remain unclear. These findings suggest that targeting KCa3.1 deficiency may alleviate joint inflammation and limit the development of persistent joint damage in experimental animal models, presenting a potential strategy for RA therapy.

**Regulatory roles of KCa3.1 in immune cells**

**Role of KCa3.1 in T cells**

The most prominent cell type in immune diseases is the T cell, which is responsible for recognizing antigens and generating immune responses. During pathogenesis of RA, autoantigens are presented to T cells by antigen-presenting cells. Following activation of pathogenic self-reactive T cells, various innate immunocytes are activated. Immediately afterwards, inflammatory signaling pathways are initiated, secreting various cytokines to trigger synovial tissue inflammation. KCa3.1 expressed in T cells initiates expression of genes that promote T cell activation and proliferation (71). Notably, stimulated activated T cells express significantly higher levels of KCa3.1 than resting T cells (22).

CD4\(^{+}\) T cells are core cells of the immune system, coordinating the adaptive immune response and regulating immune and non-immune cell functions through cytokine production (72, 73). In CD4\(^{+}\) T cells, the KCa3.1 channel is activated mainly through the phosphatidylinositol 3 phosphate (PI(3)P) signaling pathway. After antigen presentation to T cell receptors, the class II phosphatidylinositol 3 kinase C2β (PI3K-C2β) is activated, which, in turn, promotes production of PI(3)P (74). Several studies indicate that KCa3.1 channel activation by PI (3)P is associated with NDPK-B. The inhibitory effect of the 14 amino acid region at C'T of KCa3.1 is eliminated upon recruitment of nucleoside diphosphate kinase B (NDPK-B) to phosphorylate the histidine residue H358 in this region (75). Based on the above mechanism, existing studies have focused on inhibition of KCa3.1 channel opening through potential effects on three sites of activity. First, intracellular PI (3) synthesis is restricted by the PI(3)P phosphatase myotubularin-related protein 6 (MTMR6). Consistently, the highly selective PI3K inhibitor wortmannin depletes intracellular PI(3)P that results in inhibition of KCa3.1 (75, 76). Second, phosphoglycerate mutase family 5 (PGAM5) induces dephosphorylation of NDPK-B and directly inhibits NDPK-B-mediated histidine phosphorylation, thereby blocking KCa3.1 channel activation (77). Third, the mammalian protein histidine phosphatase (PHPT-1) binds directly to phosphorylated H358, triggering its dephosphorylation to achieve inhibition of KCa3.1 channel activity (78). Moreover, intracellular copper deficiency is associated with elevated H358 phosphorylation, implying that the use of copper chelators may enhance the activity of KCa3.1 (79). In an established KCa3.1\(^{-/-}\) mouse model, it was observed that T helper (Th)-0, Th1, and Th2 cells isolated from KCa3.1\(^{-/-}\) mouse are defective in Ca\(^{2+}\) flux and cytokine production, while the Th17 and Treg subsets displayed normal function. The above phenomenon supports a key role of KCa3.1 in Th0, Th1, and Th2-mediated diseases, including RA, colitis, and several other immune inflammatory disorders (80). Consistently, pharmacological inhibition of KCa3.1 decreased inflammatory bowel disease mice symptoms via increasing IL-10 production in Treg cells, suggests that KCa3.1 is responsible for the invalidation of anti-inflammatory efficiency of Treg cells in chronic inflammatory disorders (81, 82).

CD8\(^{+}\) cells are cytotoxic T lymphocytes that infiltrate solid tumors to perform immune surveillance functions. Chimote et al. provided evidence of compartmental reduction of CaM levels at the plasma membrane of CD8\(^{+}\) T cells in head and neck squamous cell carcinoma (HNSCC) patients, leading to decreased activity and chemotaxis of KCa3.1 (83). Similarly, another recent study showed that targeted KCa3.1 activation could restore the chemotaxis ability of HNSCC CD8\(^{+}\) T cells in the presence of adenosine (84). Furthermore, KCa3.1 is reported to support the migration of...
CD8+ T cells. Reduced K+ channel activity could be restored by cytokines, ultimately leading to functional recovery of impaired CD8+ T cells, facilitating clearance of pathogens or control of local tissue inflammation (85).

Role of KCa3.1 in B cells

The primary function of B cells is to differentiate into plasma cells that secrete antibodies to mediate humoral immune response under conditions of antigen stimulation and Th cell assistance. In RA condition, abnormal activation of B cells lead to autoantibodies secretion following autoantigen presentation by certain antigen presenting cells. In addition, B cells can regulate bone formation in RA by inhibiting differentiation of osteoblasts (86). Other than supporting T cell proliferation, KCa3.1 coordinates the proliferation and migration of B cells. KCa3.1 is reported to be expressed in B cells and activity of the channel is significantly elevated during differentiation of activated naive B cells into memory B cells (87, 88). As professional antigen-presenting cells, B cells play a significant role in the adaptive immune response. Mechanistically, B cells ingest, process, and present antigens by expressing the B cell receptor (BCR) and regulating the human leukocyte antigen HLA-DO (89). Non-competitive anti-N-methyl-D-aspartate-receptor (NMDAR) antagonists modulate BCR-induced B cell proliferation, migration, and production of the anti-inflammatory factor interleukin-10 (IL-10) through negative regulation of the KCa3.1 channel (88). KCNN4 encoding KCa3.1 has been characterized as a tissue-specific transcriptional coactivator (OCA-B)-dependent gene involved in B cell proliferation and function that is required for antigen-dependent B cell differentiation.

In contrast to the above findings, KCa3.1 has been shown to be positively engaged in BCR-induced B cell proliferation but not required during the active phase of B cell differentiation (90). After TRAM-34 treatment, the ability of B lymphocytes to proliferate was weaker and expression of chemokine (C-C motif) ligand 7, a chemotactic-related factor that promotes B cell migration, significantly decreased (91). While the underlying mechanisms have not been established, it is reasonable to speculate that Ca2+-associated changes are significantly linked to inhibition of KCa3.1 channel in B cells. At the molecular level, activation of the extracellular signal-regulated kinase (ERK) upstream protein RAS affects the ERK signaling pathway, leading to reduced secretion of B cell chemokines and recruitment of inflammatory cells (92).

Role of KCa3.1 in macrophages

Macrophages play a fundamental role in the pathogenesis of RA disease, with significant infiltration at the inflamed synovium and cartilage junction, promoting inflammation by secreting cytokines and chemokines (93). Studies demonstrated that macrophages may contribute to RA synovial inflammation through activation of Notch signaling, leading to M1 pro-inflammatory phenotype, or via c-Jun N-terminal kinase (JNK) signaling channels activating nuclear factor-kB and producing large amounts of tumor necrosis factor-α (TNF-α) (94). Earlier in vitro studies have demonstrated KCa3.1 expression in macrophages, with key roles in regulation of macrophage proliferation, migration, reactive oxygen species (ROS), and cytokine production (95, 96). In keeping with its role in T and B cells, KCa3.1 is reported to block the KCa3.1 channel in a study by Xu et al., the activity of signal transducer and activator of transcription 1 (STAT-1) protein was inhibited and phosphorylation levels reduced in macrophages (98). Moreover, the levels of pro-inflammatory cytokines and chemokines were significantly decreased in M1 macrophages whereas markers in M2 macrophages remained unchanged, suggesting that the KCa3.1 channel mainly regulates the function of M1 type macrophages and expression of pro-inflammatory genes. In chronic diseases, such as RA, multinucleation of macrophages is a critical step in the formation, differentiation and activation of osteoclasts, which lead to bone erosion and long-term inflammation (99, 100). In a microarray analysis of fused rat macrophages and human monocytes forming osteoclasts by Kang et al., the role of KCNN4 as a potential modulator of multinucleation was validated (69). The main downstream effect of nuclear factor-kB (NF-kB) activation is upregulation of T cell dephosphorylation by nuclear translocation of nuclear factor cytoplasmic 1 (NFATc1), which stimulates Ca2+ signaling and activates Akt. Silencing or blockage of KCa3.1 suppressed NFATc1 expression and Akt activation, implying that KCNN4 is also closely associated with cell death (69). Another study reported that TNF-α mediates the NF-kB pathway through increased autocrine secretion. NF-kB binds directly to the promoter region of KCNN4 and enhances its activity to upregulate gene expression and promote cell proliferation (101). Furthermore, blockade of the KCa3.1 channel with TRAM-34 negatively regulates NF-kB and STAT3 signaling and impairs the ability of macrophages to differentiate into the pro-inflammatory M1 phenotype, in parallel with reduced levels of inflammatory factors, such as interleukin-1 (IL-1), interleukin-6 (IL-6), TNF-α and monocyte chemoattractant protein-1 (MCP-1) (102). The majority of studies indicate that the role of KCa3.1 in macrophages is closely associated with NF-kB and STAT signaling pathways.

Role of KCa3.1 in mast cells

Mast cells (MCs) recognize endogenous and exogenous mediators, which boost the release of various mediators from
other immune and non-immune cells, consequently regulating different physiological activities in vivo (103). During the process of RA, activated MCs produce an array of pro-inflammatory mediators that activate other immune system cells, initiating and maintaining the inflammatory response. TNF-α preformed by mast cells initiates an inflammatory cascade response promoting cytokine expression. Meanwhile, products of mast cells, in particular, histamine and TNF-α, promote proliferation and catabolic effects of articular chondrocytes and synovial stromal cells, leading to the development of RA (104). A number of previous studies have confirmed the presence of KCa3.1 in mast cells. Activation of the KCa3.1 channel maintains high concentrations of intracellular free Ca²⁺ in mast cells, promotes IgE-dependent histamine release, and regulates the secretory responses of mast cells (105). The Orai/CRACM1 ion channel provides the major Ca²⁺ influx pathway for mast cells to release mediators and activation of the KCa3.1 channel in mast cells is highly dependent on this process (106). Prostaglandin E2 (PGE2) suppresses the IgE-dependent cell activation pathway by inhibiting activation of EP2 receptors. Inactivation of EP2 receptors limits the influx of free cytoplasmic Ca²⁺, leading to reduced chemokine production and subsequent closure of the KCa3.1 channel (107). Upon interference with channel gene expression via lentiviral targeting of KCa3.1, signaling pathways are disrupted and mast cell activity is reduced, followed by attenuation of the immune inflammatory response (108). In addition, E3 ubiquitin ligase (containing a tripartite motif of protein 27) negatively regulates high-affinity receptor for IgE (FcepsilonRI) activation and downstream signaling of KCa3.1 through ubiquitination and inhibition of PI3KC2 (109). The levels of chemokine CXC motif chemokine ligand 10, chemokine stem cell factor, and TNF-α in mast cells are reported to be significantly decreased by charybdotoxin and TRAM-34, along with diminished mast cell migration capacity (110).

Role of KCa3.1 in dendritic cells

Dendritic cells (DCs) participate in the presentation of autoantigens and production of pro-inflammatory factors, which contribute to ongoing inflammation in RA. In addition, DCs are in charge of maintenance and differentiation of autoimmune B and T cells which directly participated in RA pathogenesis (111). Studies show that the binding of lymphatic chemokines CCL19 and CCL21 to their receptor CCR7 induces mobilization of Ca²⁺ stored in mature DCs and subsequent opening of the KCa3.1 channel (112, 113). The migratory capacity of DCs is tightly regulated by the intracellular Ca²⁺ concentration and chemokine receptors are differentially expressed in DCs at two stages of maturation. In the presence of TRAM-34, temporal coupling between KCa3.1 and Ca²⁺ inward flow was shown to be disrupted and subsequent CCR7-induced chemotaxis impaired (112). Paradoxically, KCa3.1 exhibited migratory capacity only in immature dendritic cells and expression of its migration marker CCR5 was modified in the presence of TRAM-34 (114, 115). Data from the above study additionally confirmed that activation of T lymphocyte proliferation by dendritic cells is not affected by KCa3.1. In vitro, prevention of [Ca²⁺]i elevation under conditions of KCa3.1 deficiency decreased the directed migration of lipopolysaccharide (LPS)-challenged DCs, supporting the involvement of KCa3.1 in LPS-induced DC migration (116).

Roles of KCa3.1 in other immune cells

In RA, neutrophils can activate other immune cells that perpetuate inflammation and lead to the destruction of cartilage and bone in affected joints. This pathogenic effect occurs primarily through mechanisms including increased cell survival and migration capacity, abnormal inflammatory activity, elevated oxidative stress, and exacerbated neutrophil extracellular trap formation (117). Recently, Henriquez et al. demonstrated the existence of KCa3.1 in mammalian neutrophils for the first time and showed a positive correlation between upregulation of the channel and neutrophil migration (118). Concomitantly, targeted KCa3.1 inhibition altered the capacity of cells to properly regulate cell volume and limited neutrophil migration in vitro with no effect on Ca²⁺ homeostasis. Likewise, the membrane potential of the KCNN4⁻/⁻ neutrophil subpopulation was balanced in a study by Grimes et al., resulting in a homogeneous lower-calcium (Ca²⁺) response (119). In addition, erythrocytes have a partial immune function although they are not conventional immune cells. The KCa3.1 channel present on erythrocytes releases cellular volume by transporting K⁺ across the membrane and its activity increases in response to high cytokine levels (120). The role of KCa3.1 in immune cells has been summarized in the Table 2.

Correlative regulation of KCa3.1 and immune-inflammatory cytokines

Synovial inflammation is a critical process in the pathogenesis of RA and directly associated with clinical symptoms, such as inflammatory pain, joint swelling and progressive destruction of multiple joints. Accumulating evidence suggests that the KCa3.1 channel is capable of cytokine regulation with potential significant implications in immune-inflammatory diseases (Figure 2). KCa3.1 has been shown to stimulate TGF-β1 production. In experiments by C. Huang et al., treatment with TRAM-34 suppressed transcription of TGF-β1 and TGF-β1 type II receptor mRNA and negatively regulated phosphorylation of Smad2/3 (122). The above processes led to reduced production of inflammatory cytokines, PAI-1, and matrix proteins in the nucleus, with anti-inflammatory and anti-fibrotic effects. The
KCa3.1 channel is reported to mediate K⁺ efflux, promote intracellular Ca²⁺ concentrations, and activate calmodulin kinase IV (CaMKIV), which facilitates CREB phosphorylation, contributing to upregulation of c-fos/AP-1 and NFATc1 expression, and ultimately leading to osteoclast formation (123). Moreover, NF-κB and STAT3 signaling pathways are inactivated upon blockade of the KCa3.1 channel. Consequently, decreased secretion of pro-inflammatory factors, such as IL-1β, IL-6, TNF-α, and MCP-1, limits the progression of inflammation (102). In regulatory T cells, suppression of KCa3.1 channel activity initiates phosphorylation of JNK and c-Jun, activation of JNK/c-Jun signaling, and E4BP4/Blimp1-mediated anti-inflammatory IL-10 cytokine secretion (81, 82). The above findings suggest that inhibition of KCa3.1 channel activity modulates immune-inflammatory factors and alleviates inflammation. Paradoxically, TRAM-34 is reported to activate two types of transcriptional regulators, KLF4 and/or TRIM33, and mediate inflammation (124). SKA-31, a KCa3.1 activator, in rats (124).

The KCa3.1 channel both regulates and is regulated by cytokines (Figure 3). TGF-β1 has the capability to inhibit catalase activity and promote hydrogen peroxide levels, thereby inducing an increase in KCa3.1 expression. The p38MAPK signaling pathway plays a vital role in stress responses, such as inflammation and apoptosis. p38MAPK/AP-1/NF-κB signaling activates the AP1 complex (composed of c-fos and c-jun) and promotes transcription and translation of KCa3.1 (125). Upregulation of KCa3.1 stimulates the expression and production of interferon-γ (IFN-γ), in turn, mediating the mobilization and accumulation of inflammatory T cells, which are involved in inflammation (126). In addition, IL-1β stimulation is reported to activate NF-κB signaling and upregulate the KCa3.1 channel in pancreatic islet cells. The drug modafinil suppresses progression of inflammation via elevation of adenosine 3’, 5 cyclic monophosphate (cAMP) and inhibition of KCa3.1 channel activity (127).

### KCa3.1 as a potential drug target for RA

#### Targeting the inflammatory process of RA

The occurrence and continuous development of RA is manifested by failure of spontaneous regression of inflammation. Increasing evidence suggests that KCa3.1 promotes secretion of inflammatory factors by regulating

| Cells     | Experimental cells | Inhibition/activation of KCa3.1 | Mechanism                                      | References |
|-----------|--------------------|--------------------------------|-----------------------------------------------|------------|
| T lymphocytes | CD4⁺ T cells       | MTMR6/                          | PI(3)P¹, KCa3.1↓, proliferation↓               | (75, 76)   |
|           | CD4⁺ T cells       | Wortmannin                      |                                               |            |
|           | CD4⁺ T cells       | PGAM5                           | Dephosphorylation NDPK B, Histidine phosphorylation↓, KCa3.1↓ | (77)       |
|           | CD4⁺ T cells       | PHPT-1                          | Bind p-H358, dephosphorylation p-H358, KCa3.1↓ | (78)       |
|           | CD8⁺ T cells       | 1-EBIO                          | Chemotactic capacity↑                         | (84)       |
| B lymphocytes | Splenic B cells    | NMDAR antagonists               |                                               |            |
| Macrophages | Splenic B cells    | TRAM-34                         |                                               |            |
| Mast cells  | Human macrophages  | KCNN4 deficiency                |                                               |            |
|           | HLMC               | AH8809                          |                                               |            |
|           | P815 cells         | LV-KCa3.1-shRNA                 |                                               |            |
|           | BMMMC              | TRIM27                          |                                               |            |
|           | HLMC               | TRAM-34                         |                                               |            |
| Dendritic cells | Lung dendritic cells | TRAM-34                       |                                               |            |
|           | Immature dendritic cells | TRAM-34                      |                                               |            |

The symbols ↑ and ↓ mean the up-regulation and down-regulation of KCa3.1 expression, respectively.
immune-inflammatory cells in RA. In related reports, KCa3.1 is considered a pro-inflammatory ion channel that activates the function of inflammasome. Hydroxychloroquine is reported to impair the inflammasome and inhibit neutrophil recruitment in a dose-dependent manner through inhibition of Ca\(^{2+}\)-activated K\(^+\) conductance in THP-1 macrophages (70). Interestingly, earlier findings indicate that TGF-\(\beta\) induces transcription and translation of KCa3.1 and, conversely, silencing or inhibition of KCa3.1 negatively regulates TGF-\(\beta\) (8). In addition, the pro-inflammatory and invasive behavior of synovial fibroblasts plays an essential role in RA. Another study showed that blockade of KCa3.1 with TRAM-34 or siRNA treatment could suppress proliferation of RA-SFs. Inactivation of the channel led to downregulation of the pro-inflammatory factors IL-6, interleukin-8 (IL-8), and MCP-1, as well as tissue-destructive protease MMP3 at both mRNA and protein levels. Notably, inhibition of the KCa3.1 channel also upregulated MMP1 mRNA and enhanced secretion of IL-1\(\beta\) while decreasing that of IL1-RA, resulting in inhibition of short-term activation of Th2 lymphocytes in RA and consequently, a shift in the inflammatory homeostasis of RA to a pro-inflammatory state (41). However, limited data on the specific role of KCa3.1 in inflammation of RA are available at present. Further studies are required to elucidate the functions and mechanisms of action of KCa3.1 in the inflammatory process associated with RA.

**Targeting of cartilage destruction and bone erosion**

The pathogenesis of RA is synovial inflammation accompanied by cartilage damage and bone erosion. In addition to synovial tissue and immune cells that show critical immune-inflammatory activities, synovial fibroblasts and osteoclasts play a central role in cartilage destruction and bone erosion in RA. Although no evidence of direct mediation of RA cartilage and osteogenic destruction by KCa3.1 has been obtained, its involvement in these processes via regulation of fibroblast (FLS) and osteoclast activation is a strong possibility.

Previous studies have shown that highly activated FLS can promote inflammation and tissue invasion and mediate tissue damage with tissue-infiltrating macrophages and immune cells, such as T cells and B cells (42). FLS are involved in the pathological process of synovitis, synovial lining hyperplasia, activation of a number of synovial cells, and destruction of
cartilage matrix through production of cytokines and chemokines. The p38 MAPK (mitogen-activated protein kinase) pathway is a crucial signal transduction step during chronic inflammation (49). Two isoforms of p38MAPK, \( \alpha \) and \( \gamma \), are expressed in FLS, which play key roles in the inflammatory process by activating the p38MAPK signaling pathway to produce inflammatory factors, such as TNF-\( \alpha \), IL-1\( \beta \) and IL-6 (129). In addition, FLS regulate the proliferation and differentiation of immune cells through the p38 pathway. Transcriptional growth factor \( \beta_1 \) (TNF-\( \beta_1 \)) is highly expressed in RA-SFs and can induce expression of pro-inflammatory and pro-destructive proteins (130). TNF-\( \beta_1 \) has been shown to induce KCNN4 transcription and translation, activate the K\( \alpha \)3.1 channel, increase \( K^+ \) current, provide continuous power for \( \text{Ca}^{2+} \) influx, and promote inflammatory processes (131). At present, studies on the mechanism of action of K\( \alpha \)3.1 in synovial fibroblasts are lacking and the pathways underlying K\( \alpha \)3.1 upregulation by TGF-\( \beta_1 \) remain to be established. Further clarification of whether K\( \alpha \)3.1 has functional activity in RA-SFs through signaling pathways, such as p38MAPK (132) and NF-\( \kappa \)B (133, 134), should further support its potential involvement in RA cartilage injury.

Osteoclasts and RANKL act together to promote the occurrence of bone erosion (124, 125). In a recent study, activation of endogenous fibroblast-like synoviocytes induced RANKL expression and stimulated osteoclast formation (135, 136). The K\( \alpha \)3.1 channel inhibitors, TRAM-34 and ICA-17043, have been shown to inhibit monocyte formation in osteoclasts in a dose-dependent manner but the precise molecular mechanisms remain to be established (69). It is speculated that the K\( \alpha \)3.1 channel is functionally active in the formation of osteoclasts. K\( \alpha \)3.1 can prevent the progression of bone erosion by inhibiting the differentiation and formation of osteoclasts, thereby relieving the clinical symptoms of RA patients, providing further support for its utility in management of RA.

**Blockage of the K\( \alpha \)3.1 channel**

In applications of K\( \alpha \)3.1 channel inhibitors, existing studies indicate that TRAM-34 exerts no notable side-effects when used at a high concentration (~120 mg/kg) and has no effect on blood biochemistry and hematology parameters (137). Senicapoc has passed Phase I-III clinical trials for clinical drug use in sickle cell disease, with a reported IC\textsubscript{50} value of 11 nm (138). Senicapoc may...
cause diarrhea, nausea, and other adverse reactions in a dose-dependent manner, but overall drug safety is good. The KCa3.1 inhibitors TRAM-34 and Senicapoc have been used in RA-related in vitro studies (8, 69). Clotrimazole and nitrendipine have progressed to the clinical trial stage and are widely used to treat a number of diseases. According to the tissue distribution characteristics of the KCa3.1 channel, KCa3.1 generally not expressed in excitable tissues and reproductive organs, which indicates a low-risk, acute-toxicology profile of KCa3.1 channel blockade. The results obtained to date support the feasibility, efficacy, and safety of the KCa3.1 channel as a therapeutic target in RA. However, extensive research is required before introduction of KCa3.1 channel blockers in the clinic. Remarkably, related studies have shown that the KCa3.1 channel is the basis of slow afterhyperpolarization (SAHP) in neurons and may exert side-effects that affect sensory transmission (139).

Conclusions and outlook

KCa3.1 promotes inflammation, cartilage damage, and bone erosion in synovial fibroblasts and osteoclasts that are mechanistically involved in development of RA. Based on its ability to restore the immune balance by interfering with Ca\(^{2+}\) signaling, KCa3.1 presents a promising therapeutic target for RA. The possible functions of KCa3.1 in the pathological process of RA is shown in Figure 4. Despite interesting experimental findings to date, research in this field is still in its infancy. Considerable work remains to be done to elucidate the in-depth mechanisms underlying the involvement of KCa3.1 in RA. For example, the issue of whether KCa3.1 directly mediates cartilage and bone destruction in RA is yet to be resolved. Furthermore, no clinical trials have directly investigated the effects of KCa3.1-specific inhibitors and activators in RA as yet. In summary, KCa3.1 provides excellent research prospects for treatment of RA and further development of drugs targeting this channel may be of considerable benefit to patients.

Author contributions

RP-Z and WH conceived this project. LY and Y-JZ prepared the first draft. H-LZ, W-JH, R-DZ, YW and R-PZ revised the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by grants from the National Natural Science Foundation of China (82272450, 81902182, 82071591) and the Natural Science Foundation Incubation...
Program of the Second Hospital of Anhui Medical University (2021GMFY06).

**Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**References**

1. Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Rev Dis Primers (2018) 4:18002. doi: 10.1038/nrdp.2018.2

2. Mabry AD, Kuchel PW. The girdos channel: a review of the Ca2+-activated k+ channel in human erythrocytes. Int J Biochem Cell Biol (2003) 35(8):1182–97. doi: 10.1016/s1357-2725(03)03102-2

3. Fanger CM, Ghanshani S, Logsdon NJ, Rauer H, Kalman K, Zhou J, et al. Calmodulin mediates calcium-dependent activation of the intermediate conductance KCa channel, IKCa1. J Biol Chem (1999) 274(9):5746–54. doi: 10.1074/jbc.274.9.5746

4. Wulf H, Castle NA. Therapeutic potential of KCa3.1 blockers: recent advances and promising trends. Expert Rev Clin Pharmacol (2010) 3(3):385–96. doi: 10.1586/ercp.10.11

5. Hara MR, Snyder SH. Cell signaling and neuronal death. Annu Rev Pharmacol Toxicol (2007) 47:117–41. doi: 10.1146/annurev.pharmtox.47.120505.105311

6. Huang C, Pollock CA, Chen XM. Role of the potassium channel KCa3.1 in diabetic nephropathy. Clin Sci (Lond) (2014) 127(4):423–33. doi: 10.1042/CS20140077

7. Koch Hansen L, Sevelsted-Møller L, Rabjerg M, Larsen D, Hansen TP, Klinge L, et al. Expression of T-cell Kv1.3 potassium channel correlates with pro-inflammatory cytokines and disease activity in ulcerative colitis. J Crohns Colitis (2014) 8(4):1178–91. doi: 10.1016/j.crohns.2014.04.003

8. Frielie K, Schonher R, Kinne RW, Kunisch E. Functional role of the KCa3.1 potassium channel in synovial fibroblasts from rheumatoid arthritis patients. J Cell Physiol (2015) 230(7):1677–84. doi: 10.1002/JCP.24924

9. Zhao J, Guo S, Schrodi SJ, He D. Molecular and cellular heterogeneity in chromosome 19q13.2 in the region deleted in diamond-blackfan anemia. Curr Biochem Pharmacol Res Perspect (2018) 4:18002. doi: 10.1038/jgp.201210933

10. Jones HM, Hamilton KL, Papworth GD, Syme CA, Watkins SC, Bradbury NA, et al. Role of the NH2 terminus in the assembly and trafficking of the intermediate conductance Ca2+-activated k+ channel hIK1. J Biol Chem (2004) 279(15):15531–40. doi: 10.1074/jbc.M400099200

11. Syne CA, Hamilton KL, Jones HM, Gerlach AC, Gilman LP, Papworth GD, et al. Trafficking of the Ca2+-activated k+ channel, IK1, is dependent upon a terminal leucine zipper. J Biol Chem (2003) 278(10):8476–86. doi: 10.1074/jbc.M210072200

12. Lin ET, Kito H, Hatano N, Muraki K. Recent advances in therapeutic strategies that focus on the regulation of ion channel expression. Pharmacol Ther (2016) 160:11–45. doi: 10.1016/j.pharma.2016.02.001

13. Ghanshani S, Wulf H, Miller MJ, Rohm H, Neben A, Gutman GA, et al. Up-regulation of the IKCa1 potassium channel during T-cell activation. J Biol Chem (2000) 275(27):41373–49. doi: 10.1074/jbc.M003941200

14. Takai J, Santu A, Zheng H, Koh SD, Ohba M, Filumborn LM, et al. Laminin shear stress upregulates endothelial Cal2(2+)–activated k+ channels KCa2.3 and KCa3.1 via a Cal2(2+)–calmodulin-dependent protein kinase kinase/Akt/p300 cascade. Am J Physiol Heart Circ Physiol (2013) 305(4):H484–93. doi: 10.1152/ajpheart.00642.2012

15. Wang LP, Wang Y, Zhao LM, Li GR, Deng XL. Angiotensin II upregulates K(Ca)3.1 channels and stimulates cell proliferation in rat cardiac fibroblasts. Biochem Pharmacol (2013) 85(10):1486–94. doi: 10.1016/j.bcp.2013.02.032

16. Lai W, Chen S, Wu H, Guan Y, Liu Z, Zeng Y, et al. PRL-3 promotes the proliferation of LoVo cells via the upregulation of KCN4 channels. Oncol Rep (2011) 26(4):909–17. doi: 10.3892/or.2011.1366

17. Cheong A, Bingham AJ, Li J, Kumar B, Sukumar P, Munsch C, et al. Downregulated REST transcription factor is a switch enabling critical potassium channel expression and cell proliferation. Mol Cell (2005) 20(1):45–52. doi: 10.1016/s0022-2802(04)00228-6

18. Morales P, Garneau L, Klein H, Laviose MF, Parent L, Sauvi R. Contribution of the KCa3.1 channel-calcium interactions to the regulation of the KCa3.1 gating process. J Gen Physiol (2013) 142(1):37–46. doi: 10.1085/jgp.201210933

19. Jones HM, Hamilton KL, Papworth GD, Syne CA, Watkins SC, Bradbury NA, et al. Role of the NH2 terminus in the assembly and trafficking of the intermediate conductance Ca2+-activated k+ channel hIK1. J Biol Chem (2004) 279(15):15531–40. doi: 10.1074/jbc.M400099200

20. Syne CA, Hamilton KL, Jones HM, Gerlach AC, Gilman LP, Papworth GD, et al. Trafficking of the Ca2+-activated k+ channel, IK1, is dependent upon a terminal leucine zipper. J Biol Chem (2003) 278(10):8476–86. doi: 10.1074/jbc.M210072200

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
activated potassium channels and their therapeutic indications. *Curr Med Chem* (2007) 14(1):1437–57. doi: 10.2174/092986707778031186.

33. De Marchi U, Basalingappa KM, Rajendran YM, Wonderlin WF. Characteristics of KCn4 channels in the apical membranes of an intestinal epithelial cell line. *Am J Physiol Gastrointest Liver Physiol* (2011) 30(1):G505–11. doi: 10.1152/ajpgi.00558.2010.

34. Hammad R, Chang MC, Joiner WJ, Kacmarek LR, Schlachter LC. hIK4- hIK1, a calmodulin-binding KCa channel in human T lymphocytes. roles in proliferation and volume regulation. *J Biol Chem* (1999) 274(1):14388–9. doi: 10.1074/jbc.21.14388.

35. Vanzi P, Gossani LD, Rodriguez de la Vega BC, Gasparr R, Varga Z. K+ channel blockers: novel tools to inhibit T cell activation leading to specific immunosuppression. *Curr Pharm Des* (2006) 12(18):2199–220. doi: 10.2174/138161206778157575.

36. Feske S, Wulff H, Skolnik EY. Ion channels in innate and adaptive immunity. *Annu Rev Immunol* (2015) 33:293–351. doi: 10.1146/annurev-immunol-031214-122112.

37. Blomster LV, Strobaek D, Hoogard C, Klein J, Pinborg LH, Mikkelsen JD, et al. Quantitation of the functional expression of the Ca(2+)-activated K+ channel KCa 3.1 on microglia from adult human neonatal tissue. *Glut* (2016) 64.1(2065–73). doi: 10.1002/glia.23040.

38. Todd G, Munoz L, Herrmann M, Schett G, Balog A. The effects of Kv.3.1 and IKCa1 channel inhibition on cytokine production and calcium influx of T lymphocytes in rheumatoid arthritis and ankylosing spondylitis. *Immunol Res* (2016) 64(2):627–31. doi: 10.1007/s12026-015-8683-8.

39. Weyand GM, Goronzy JJ. The immunology of rheumatoid arthritis. *Nat Immunol* (2021) 22(11):10–8. doi: 10.1038/s41590-020-0016-x.

40. Devor DC, Singh AK, Frizzell RA, Bridges RJ. Modulation of Cl− secretion by KCa 3.1 channel blocker in mice. *J Physiol* (1996) 271(5 Pt 1):L775–8. doi: 10.1113/physiol.1996.271.5.L775.

41. Manfoni G, Gagone F, Monarca L, Astolfi A, Mancinelli L, Iannitti RG, et al. New insights on KCa3.1 channel modulation. *Curr Pharm Des* (2020) 26(18):2096–101. doi: 10.2174/13816128266660316152645.

42. Brown BM, Shim H, Zhang M, Yarov-Yarovoy V, Wulff H. Structural determinants for the selectivity of the positive KCa3.1 gating modulator 5-Methylphosphonate-[2,1-dioxo-2-amine] (SKA-121). *Mol Pharmacol* (2017) 92(4):469–80. doi: 10.1124/mol.116.109421.

43. Strobaek D, Treuber L, Jorgensen TD, Ahlgren PK, Kjaer K, Hansen RS, et al. Activation of human IK and SK Ca2+-activated k+ channels by NS09 (6,7-dichloro-1H-indole-2,3-dione-3-oxime). *Biochim Biophys Acta* (2004) 1665(1-2):1–5. doi: 10.1016/j.bbamem.2004.07.006.

44. Ehrlich BE, Kaffman B, Bezprozvanny B, Bezprozvanny I. The pharmacology of intracellular Ca(2+)-release channels. *Trends Pharmacol Sci* (1994) 15(5):145–9. doi: 10.1016/0166-6851(94)90074-4.

45. Wong R, Schlachter LC. PKA reduces the rat and human KCa3.1 current, CaM binding, and Ca2+ signaling, which requires Ser332/334 in the CaM-binding c terminal. *Neurosci* (2014) 264(1):1371–83. doi: 10.1016/j.neuroscience.2014.08.014.

46. Liao CR, Wang SN, Zhu SY, Wang YQ, Li ZZ, Liu YZ, et al. Advanced oxidation protein products increase TNF-α and IL-1β expression in chondrocytes via NADPH oxidase 4 and accelerated cartilage degradation in osteoarthritis progression. *Redox Biol* (2020) 28:101306. doi: 10.1016/j.redox.2019.101306.

47. Schroder RL, Jensen BS, Strobaek D, Olesen SP, Christophersen P. Activation of the human, intermediate-conductance, Ca2+-activated k+ channel by methanethansione. *Pflugers Arch* (2000) 440(4):809–18. doi: 10.1007/s004240000364.

48. Syne CA, Gerlac AC, Singh AK, Devor DC. Pharmacological activation of cloned intermediate- and small-conductance Ca(2+)-activated k(+) channels. *Am J Physiol Cell Physiol* (2000) 278(3):C3570–C3581. doi: 10.1152/ajpcell.2000.278.3.C3570.

49. Gerlac AC, Syne CA, Gillinan L, Adelmann JP, Devor DC. ATP-dependent activation of the intermediate conductance, Ca2+-activated k+ channel, hIK1, is conferred by a c-terminal domain. *J Biol Chem* (2001) 276(14):10963–70. doi: 10.1074/jbc.M007176200.
84. Wang Y, Han CC, Cui D, Li Z, Ma Y, Wei W. Is macrophage polarization important in rheumatoid arthritis? Int Immunopharmacol (2017) 50:345–52. doi: 10.1016/j.immuni.2017.07.019
85. Toyama K, Wulff H, Chandy KG, Aram P, Raman G, Saito T, et al. The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans. J Clin Invest (2008) 118 (9):3025–37. doi: 10.1172/JCI30836
86. Hanley PJ, Musset B, Renugunta V, Limberg SH, Dalpke AH, Sus R, et al. Extracellular ATP induces oscillations of intracellular Ca2+ and membrane potential and promotes transcription of IL-1 in macrophages. Proc Natl Acad Sci U S A (2004) 101(25):9479–84. doi: 10.1073/pnas.0400733101
87. Zhu Y-R, Jiang X-X, Zhang D-M. Critical regulation of atherosclerosis by the KCa3.1 channel and the retargeting of this therapeutic target in in-stent neoatherosclerosis. J Mol Med (Berl) (2019) 97(1):129–29. doi: 10.1007/s00109-019-01814-9
88. Xu R, Li C, Wu Y, Shen L, Ma J, Qian J, et al. Role of KCa3.1 channels in macrophage polarization and its relevance in atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol (2017) 37(2):226–36. doi: 10.1161/ATVBAHA.116.306461
89. Yagi M, Miyamoto T, Sawatani Y, Iwamoto K, Hosogane N, Fujita N, et al. DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med (2005) 202(3):345–51. doi: 10.1084/jem.20050645
90. Zhu XW, Price NM, Gilman RH, Recarvarren S, Friedland JS. Multinucleate giant cells release functionally unopposed matrix metalloproteinase 9 in vitro and in vivo. J Infect Dis (2007) 196(7):1076–9. doi: 10.1086/521030
91. Xu H, Lai W, Zhang Y, Liu I, Luo X, Zeng Y, et al. Tumor-associated macrophage-derived IL-6 and IL-8 enhance invasive activity of LoVo cells induced by FRL-3 in a KCN4 channel-dependent manner. BMC Cancer (2014) 14:330. doi: 10.1186/1475-2840-14-330
92. Feng F, Tao Y, Liu J, Geng Z, Wang Y, Yang W, et al. KaC1.1 inhibition of macrophages suppresses inflammatory response leading to endothelial damage in a cell model of Kawasaki disease. J Inflammation Res (2021) 14:719–35. doi: 10.2147/JIR.S291373
93. Dahlén JS, Mauzer M, Metcalfe DD, Pejler G, Sagi-Eisenberg R, Nilsson G. The inguinal mast cell: Contemporary insights into mast cell behavior and function. Allergy (2012) 77(1):83–99. doi: 10.1111/all.11488
94. Woolley DE. The mast cell in inflammatory arthritis. New Engl J Med (2004) 350(17):1709–11. doi: 10.1056/NEJMcp023206
95. Mark Duffy S, Berger P, Cruse G, Yang W, Bolton SJ, Bradshaw P. The k+ channel iKCa1 potentiates Ca2+ influx and degranulation in human lung mast cells. J Clin Immunol (2004) 24(1):66–72. doi: 10.1007/jci20040405
96. Duffy SM, Ashmore I, Smallwood DT, Leyland ML, Bradshaw P, Orac/RCAM1 and KCa3.1 ion channels interact in the human lung mast cell plasma membrane. Cell Communication Signaling (2015) 13:332. doi: 10.1186/s12983-015-0112-z
97. Duffy SM, Cruse G, Cockerill SL, Brightling CE, Bradshaw P. Engagement of the EP2 prostaglandin receptor closes the k+ channel KCa3.1 in human lung mast cells and attenuates their migration. Eur J Immunol (2008) 38(9):2548–56. doi: 10.1002/eji.200738106
98. Lin H, Zheng C, Li J, Yang C, Hu L. Lentinival shRNA against KCa3.1 inhibits allergic response in allergic rhinitis and suppresses mast cell activity via PI3K/AKT signaling pathway. Sci Rep (2015) 5:13217. doi: 10.1038/srep13217
99. Srivastava S, Cai X, Li Z, Sun Y, Skelton EY. Phosphatidylinositol-3 kinase Cbeta and TRIM27 function to positively and negatively regulate IgE receptor activation of mast cells. Mol Biol Cell (2012) 23(15):3132–9. doi: 10.1091/ mbc.e11-09-0019-12
100. Cruse G, Duffy SM, Brightling CE, Bradshaw P. Functional KCa3.1 k+ channels are required for human lung mast cell migration. Thorax (2006) 61 (10):880–5. doi: 10.1136/thx.2006.060319
101. Khan S, Greenberg JD, Bhardwaj N. Dendritic cells as targets for therapy in rheumatoid arthritis. Nat Rev Rheumatol (2009) 5(10):566–71. doi: 10.1038/ nrrheum.2009.185
102. Shao Z, Makinde TO, Agrawal DK. Calcium-activated potassium channel KCa3.1 in lung dendritic cell migration. Am J Respir Cell Mol Biol (2011) 45(5):962–8. doi: 10.1165/rcmb.2010-0514OC
103. Shao Z, Gaurav R, Agrawal DK. Intermediate-conductance calcium-activated potassium channel KCa3.1 and chloride channel modulate chemokine ligand (CCL19/CCL21)-induced migration of dendritic cells. Transl Res (2015) 166 (1):89–102. doi: 10.1016/j.trsl.2014.11.010
104. Crottes D, Felix R, Meley D, Chadet H, Ferr R, Audiger C, et al. Immature human dendritic cells enhance their migration through KCa3.1 channel activation. Cell Calcium (2016) 59(4):198–207. doi: 10.1016/j.cca.2016.02.008
105. Vandier C, Velge-Rousset F. Regulation of human dendritic cell immune functions by ion channels. Curr Opin Immunol (2018) 52:27–31. doi: 10.1016/j.coi.2018.03.011
116. Grobner S, Lukowski R, Autenrieth IB, Ruth P. Lipopolysaccharide induces cell volume increase and migration of dendritic cells. Microb. Immunol. (2014) 58 (1):61–7. doi: 10.1111/1348-0421.12116

117. Cecchi I, Arias de la Rosa I, Menegatti E, Roccato L, Collantes-Esteve E, Lopez-Pedraza C, et al. Neutrophils: Novel key players in rheumatoid arthritis. Front. Immunol. 2018(17):1138–49. doi: 10.3389/fimmu.2018.01138

118. Henriquez C, Riquelme TT, Vera D, Julio-Kalajic F, Ehrenfeld P, Melvin JE, et al. The calcium-activated potassium channel KCa3.1 plays a central role in the chemotactic response of mammalian neutrophils. Acta Physiol. (Oxf) (2016) 216 (1):132–45. doi: 10.1111/alpha.12548

119. Grimes D, Johnson R, Pahos M, Cummings C, Kang C, Sampedro GR, et al. ORAI1 and ORAI2 modulate murine neutrophil calcium signaling, cellular activation, and host defense. Proc. Natl Acad. Sci. U. S. A. (2020) 117 (39):24403–14. doi: 10.1073/pnas.2008032117

120. Karsten E, Herbert BR. The emerging role of red blood cells in cytokine signaling and modulating immune cells. Blood (2020) 41:100644. doi: 10.1016/j.bleu.2019.100644

121. Srivastava S, Cai X, Li Z, Sun Y, Skolnik EY. Phosphatidylinositol-3-kinase C2β and TRIM27 function to positively and negatively regulate Igλ receptor activation of mast cells. Mol. Cell. Biol. (2012) 32 (15):3132–9. doi: 10.1128/MCB.00019-12.

122. Huang C, Shen S, Ma Q, Chen J, Gill A, Pollock CA, et al. Blockade of KCa3.1 ameliorates renal fibrosis through the TGF-beta1/Smad pathway in diabetic mice. Diabetes (2013) 62 (8):2925–34. doi: 10.2337/db13-0153.

123. Grossinger EM, Kang EM, Bouchareychas L, Sarin R, Haudenschild DR, et al. Neutrophils: Novel key players in rheumatoid arthritis. Frontiers in Immunology frontiersin.org (2021) 12(1):132

124. John CM, Khaddaj Mallat R, Mahra RC, George G, Singh V, Turnbull JD, et al. SKA-31, a novel activator of Ca(2+)-activated K(+) channels, improves cardiovascular function, and host defense. Proc. Natl Acad. Sci. U. S. A. (2020) 117 (17):1138–49. doi: 10.1073/pnas.2008032117

125. He S, Wang Y, Yao Y, Cao Z, Yin J, Zi L, et al. Inhibition of KCa3.1 suppresses atrial fibrillation via suppressing matrix metalloproteinase-1 in rheumatoid arthritis. Ann. Rheumatic Diseases (2017) 76 (8):1043–51. doi: 10.1136/ard.2016.102521

126. Matsui M, Terasawa K, Kajikuri J, Kito H, Endo K, Jaikhan P, et al. Histone deacetylases enhance Ca(2+)-activated K(+) channel KCa3.1 expression in murine macrophages. J. Immunol. (2017) 198 (12):4588–95. doi: 10.4049/jimmunol.1600989

127. Choi S, Kim JA, Li H, Jo SE, Lee H, Kim TH, et al. The calcium-activated potassium channel KCa3.1 plays a central role in inflammation and remodeling in allergic airway disease. Transplantation (2013) 95 (2):285–92. doi: 10.1097/TP.0b013e31827f2a24

128. Ferreira R, Lively S, Schlchter LC. IL-4 type 1 receptor signaling up-regulates KCNN4 expression, and increases the KCa3.1 current and its contribution to migration of alternative-activated microglia. Front. Cell. Neurosci. (2014) 8:183. doi: 10.3389/fncel.2014.00183

129. Korb A, Tohidast-Akra M, Cetin E, Axxmann R, Smolen J, Schett G. Differential tissue expression and activation of p38 MAPK alpha, beta, gamma, and delta isoforms in rheumatoid arthritis. Arthritis Rheumatol. (2006) 54(9):2745–56. doi: 10.1002/art.22080

130. Lefere S, Schwarz M, Meier FMP, Zimmermann-Geller R, Turner IH, Rickert M, et al. Disease-specific effects of matrix and growth factors on adhesion and migration of rheumatoid synovial fibroblasts. J. Immunol. (2017) 198 (12):4588–95. doi: 10.4049/jimmunol.1600989

131. Chandy KG, Wullf H, Beeton C, Pennington M, Gutman GA, Cahalan MD. K(+) channels as targets for specific immunomodulation. Trends Pharmacol. Sci. (2004) 25(5):280–9. doi: 10.1016/j.tips.2004.03.010

132. Kunisch E, Gandesiri M, Fuhrmann R, Roth A, Winter R, Kinne RW. Predominant activation of MAP kinases and pro-destructive/pro-inflammatory features by TNF alpha in early-passage synovial fibroblasts via TNF receptor-1; failure of p38 inhibition to suppress matrix metalloproteinase-1 in rheumatoid arthritis. Ann. Rheumatic Diseases (2007) 66 (8):1043–51. doi: 10.1136/ard.2006.062521

133. Xia ZB, Meng FR, Fang YX, Wu X, Zhang CW, Liu Y, et al. Inhibition of NF-κB signaling pathway induces apoptosis and suppresses proliferation and angiogenesis of human fibroblast-like synovial cells in rheumatoid arthritis. Medicine (2018) 97(23):e19920. doi: 10.1097/MD.0000000000019920

134. Li G, Xia Z, Liu Y, Meng F, Wu X, Fang Y, et al. SIRT1 inhibits rheumatoid arthritis fibroblast-like synovocyte aggressiveness and inflammatory response via suppressing NF-κB pathway. Biochim Biophys Acta (2018) 1885 (1):280–9. doi: 10.1016/j.bbagrm.2018.05.041

135. Chen Z, Bao H, Ramming A, Schett G. Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis. Nat Rev Rheumatol (2019) 15(1):9–17. doi: 10.1038/s41584-018-0109-2

136. Schett G, Gravallese E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol (2012) 8(11):656–64. doi: 10.1038/nrrheum.2012.153

137. Yu ZH, Xu JR, Wang YX, Xu GN, Xu ZP, Yang K, et al. Targeted inhibition of KCa3.1 channel attenuates airway inflammation and remodeling in allergic asthma. Am J Respir Cell Mol Biol (2013) 48(6):685–93. doi: 10.1165/rcmb.2012-0236OC.

138. Hua X, Deuse T, Chen YJ, Wulf H, Stubbendorff M, Kohler R, et al. The potassium channel KCa3.1 as a new therapeutic target for the prevention of obliterative airway disease. Transplantation (2013) 95(2):285–92. doi: 10.1097/TP.0b013e31827f2a24

139. King B, Ruwan AP, Asmara H, Heath NC, Engbers JD, Dykstra S, et al. IKCa channels are a critical determinant of the slow AHP in CA1 pyramidal neurons. Cell Rep (2015) 11(2):175–82. doi: 10.1016/j.celrep.2015.03.026
**Glossary**

1-EBIO 1-Ethyl-2-benzimidazolidinone

AP-1 activation protein-1

BCR B cell receptor

BMMC bone marrow-derived mast cells

CAIA collagen antibody-induced arthritis

CaM calmodulin

CAMBD CAM-binding domain

cAMP adenine 3', 5 cyclic monophosphate

CHO cells Chinese hamster ovary cells

CIA collagen-induced arthritis

CRE cAMP response element

CVID common variable immunodeficiency

CZ chlorzoxazone

dCs dendritic cells

DC-EBIO 5, 6-dichloro-1-EBIO

DMARDs disease-modifying anti-rheumatic drugs

EC50 effective concentration producing 50% of maximum response

FLS fibroblast-like synoviocytes

GC glucocorticoids

H-89 N-[2-(4-bromocinnamylamino)ethyl]-5-isoquinoline-3-one

HDAC histone deacetylase

HEK-293 cells human embryonic kidney cells

HNSCC head and neck squamous cell carcinoma

IBMX 3-isobutyl-1-methylxanthine

IC50 inhibitory concentration (e.g. 50% inhibition of maximum)

IFN-γ interferon-γ

IGFBP5 insulin-like growth factor-binding protein 5

IL interleukin

JNK c-Jun N-terminal kinase

KCa3.1 intermediate conductance Ca2+-activated K+ channel

LPS lipopolysaccharide

LZ leucine zipper

MAPK mitogen-activated protein kinase

MCP-1 monocyte chemotractant protein-1

MCs mast cells

MGCs multinucleated macrophages

MTMR6 myotubularin-related protein 6

MTX Maurotoxin

NDPK-B nucleoside diphosphate kinase B

NFATc1 nuclear translocation of nuclear factor cytoplasmic 1

NF-κB nuclear factor-κB

NMDAR anti-N-methyl-D-aspartate-receptor

NS509 6, 7-dichloro-1H-indole-2, 3-dione-3-oxime

NS6180 4-[[3-(trifluoromethyl) phenyl] methyl]-2H-1, 4-benzoazin-3 (4H)-one

NSAIDs non-steroidal anti-inflammatory drugs

NS6180 4-[[3-(trifluoromethyl) phenyl] methyl]-2H-1, 4-benzoazin-3 (4H)-one

NSAIDs non-steroidal anti-inflammatory drugs

PGAM5 phosphoglycerate mutase family 5

PGE2 prostaglandin E2

PHPT-1 protein histidine phosphatase

PI3K phosphatidylinositol 3-kinase

PI3K-C2β the class II phosphatidylinositol 3 kinase C2β

PI(3)P phosphatidylinositol 3 phosphate

PKA cAMP-dependent protein kinase

RA rheumatoid arthritis

RANKL receptor activator of nuclear factor-κB ligand

REST repressor element 1-silencing transcription

SKA-121 5-methylnaptho [2, 1-d] oxazol-2-amine

SKA-31 Naphtho [1, 2-d] thiazole-2-ylamine

STAT-1 signal transducer and activator of transcription 1

TNF-α tumor necrosis factor-α

TNF-β1 transcriptional growth factor β1

TRAM-34 1-[(2-chlorophenyl) diphenylmethyl]-1H-pyrazole

TRIM27 tripartite motif containing protein 27

ZOX zoxazolamide

 Continued

PGAM5 phosphoglycerate mutase family 5

PGE2 prostaglandin E2

PHPT-1 protein histidine phosphatase

PI3K phosphatidylinositol 3-kinase

PI3K-C2β the class II phosphatidylinositol 3 kinase C2β

PI(3)P phosphatidylinositol 3 phosphate

PKA cAMP-dependent protein kinase

RA rheumatoid arthritis

RANKL receptor activator of nuclear factor-κB ligand

REST repressor element 1-silencing transcription

SKA-121 5-methylnaptho [2, 1-d] oxazol-2-amine

SKA-31 Naphtho [1, 2-d] thiazole-2-ylamine

STAT-1 signal transducer and activator of transcription 1

TNF-α tumor necrosis factor-α

TNF-β1 transcriptional growth factor β1

TRAM-34 1-[(2-chlorophenyl) diphenylmethyl]-1H-pyrazole

TRIM27 tripartite motif containing protein 27

ZOX zoxazolamide

(Continued)